ストックスクリーナーアプリを入手
3.22
3.21%
0.10
アフターアワーズ：
3.22
前日終値:
$3.12
開ける：
$3.1
24時間の取引高:
16,412
Relative Volume:
0.31
時価総額：
$28.02M
収益：
-
当期純損益:
$-30.16M
株価収益率:
-9.4706
EPS:
-0.34
ネットキャッシュフロー:
$-39.49M
1週間 パフォーマンス:
-2.42%
1か月 パフォーマンス:
-2.42%
6か月 パフォーマンス:
-11.29%
1年 パフォーマンス:
+879.02%
1日の値動き範囲:
$3.10
$3.2999
1週間の範囲:
$3.0301
$3.315
52週間の値動き範囲:
$0.28
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
DARE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
3.22 | 28.02M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.76 | 104.50B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.19 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.16 | 37.08B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.62 | 30.13B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.30 | 27.64B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dare Bioscience Inc (DARE) 最新ニュース
Daré Bioscience, Inc. and ARPA-H Ring the Closing Bell - Nasdaq
Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average – Time to Sell? - Defense World
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream Development to Address Female Sexual Arousal Disorder - Defense World
Daré Bioscience to initiate phase 3 study of FSAD treatment - Investing.com
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) - The Manila Times
Daré Bioscience Announces Phase 3 Plans for Sildenafil - GlobeNewswire
Daré Bioscience Advances First-Ever FSAD Treatment: Phase 3 Trial Set for Breakthrough Female Sexual Health Drug - StockTitan
Daré Bioscience Announces Publication in Sexual Medicine of - GlobeNewswire
Daré Bioscience's Sildenafil Cream Shows Promising Clinical Data for Female Sexual Health Treatment - StockTitan
Daré Bioscience receives $2.5 million for contraceptive tech By Investing.com - Investing.com Canada
Daré Bioscience receives $2.5 million for contraceptive tech - Investing.com India
DAREDare Bioscience, Inc. Latest Stock News & Market Updates - StockTitan
Daré Bioscience Announces $2.5 Million Grant Funding - GlobeNewswire
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - The Manila Times
Daré Bioscience Advances Revolutionary Wireless Contraceptive Tech With $2.5M Grant Milestone - StockTitan
Dare Bioscience Q3 2024 Earnings Preview - MSN
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Dare Bioscience Inc (DARE) Quarterly 10-Q Report - Quartzy
Form 10-Q Dare Bioscience, Inc. For: Sep 30 - StreetInsider.com
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Daré Bioscience Secures $35.7M in Funding, Cuts R&D Costs by 60% in Q3 Report | DARE Stock News - StockTitan
Daré Bioscience Announces Grant to Support Development of a - GlobeNewswire
Daré Bioscience secures $10.7 million grant from Gates Foundation - Investing.com India
Daré Bioscience secures $10.7 million grant from Gates Foundation By Investing.com - Investing.com UK
Daré Bioscience Lands $10.7M Gates Foundation Grant for Novel Contraceptive Development | DARE Stock News - StockTitan
Daré Bioscience (DARE) Scheduled to Post Earnings on Thursday - Defense World
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 - The Manila Times
Daré Bioscience to Host Third Quarter 2024 Financial - GlobeNewswire
Daré Bioscience to Report Q3 2024 Earnings, Host Conference Call November 14 | DARE Stock News - StockTitan
Daré Lands $25M for Women-Centric Pipeline - San Diego Business Journal
Dare BioscienceCatering To Women - RTTNews
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Will It Be A December To Remember For Daré Bioscience? - RTTNews
Daré Bioscience (NASDAQ:DARE) Publishes Corporate Presentation - Defense World
Daré Bioscience Enhances Investor Engagement with New Presentation - TipRanks
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience shares retain Buy rating on funding reward By Investing.com - Investing.com Canada
FemTech start-ups share in $110m Sprint for Women's Health - substack.com
Dare Bioscience awarded $10M for HPV treatment development - Investing.com India
Dare Bioscience awarded $10M for HPV treatment development By Investing.com - Investing.com South Africa
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health - The Bakersfield Californian
Daré Bioscience Enters Purchase Agreement with Lincoln Park Capital Fund - Defense World
Dare Bioscience secures $15 million funding agreement By Investing.com - Investing.com Australia
Dare Bioscience secures $15 million funding agreement - Investing.com
Dare Bioscience Inc (DARE) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
大文字化:
|
ボリューム (24 時間):